Understanding Compassionate Use and Early Access Programs

Patients with serious, life-threatening, or rare disorders often have limited treatment options. In several cases, approved treatments may be unavailable, ineffective, or inaccessible in their country. In such cases, Expanded Access Programs (EAPs) may establish a pathway for eligible patients to access investigational medicines. These programs are for those who may benefit from treatment before the medicine receives full commercial approval. 

Expanded Access Programs are important in global healthcare by helping bridge the gap between clinical development and commercial availability. These programs are widely used in oncology, hematology, neurology, immunology, rare diseases, and other specialty therapeutic areas where patients may urgently need specialty treatments.

Ikris Pharma Network supports patients and clinicians by facilitating access to investigational medicines through compliant patient access pathways worldwide

What is an Expanded Access Program (EAP)?

• Advanced cancers
• Rare diseases
• Genetic disorders
• Neurological conditions
• Serious chronic illnesses
• Hematologic malignancies
  

Why Expanded Access Programs Matter?

Medical research continues to accelerate, with thousands of investigational medicines being manufactured worldwide. However, there are several patients who cannot wait for lengthy approval processes when already struggling with serious illnesses.

Expanded Access Programs help address this challenge by providing patients with access to therapies before they become commercially available.

For several patients, these programs may represent:

• An additional therapeutic option when approved therapies have not worked
• Access to specialty medicines before market launch
• Continued treatment following clinical trial participation
• Access to therapies not yet available in their country
  

By creating structured pathways for medicine access, EAPs help support patient while maintaining regulatory oversight and safety standards.

Global Demand for Expanded Access Programs:

The need for Expanded Access Programs (EAPs) is very high as precision medicine, targeted therapies, gene therapies, biologics, and rare disease treatments become so important.  Many life-saving medicines receive regulatory approval in very few countries years before becoming available everywhere. During this time-span, patients and physicians often access through Expanded Access Programs.

EAPs are important in:

• • Oncology
    
  • Hematology
  • Neurology
  • Immunology
  • Genetic Disorders
  • Rare Diseases
  • Advanced Cell and Gene Therapies
  
  
  As healthcare industry embracing personalized medicine, demand for patient access programs (PAPs) is expected to continue increasing worldwide.
  
  

  Industry Insights and Patient Access Statistics:

  According to the World Health Organization (WHO), over 300 million people worldwide are estimated to be living with a rare disease. These numbers highlight the significant unmet medical needs faced by patients worldwide. Many of these patients may need access to specialty therapies through Expanded Access Programs (EAPs), Compassionate Use Programs (CUPs), or other patient access pathways. 
  

  
  

  These factors highlight the high importance of patient access pathways in modern healthcare.

  
  Who Qualifies for an Expanded Access Program?

  Patients who may qualify for this program generally meet one or more of the following criteria:

  • Serious or Life-Threatening Condition: The patient has a life-threatening disease requiring urgent medical intervention.
  • No Approved Treatment Available: No approved treatment exists for the patient's condition.
  • Exhausted Available Treatment Options: Available therapies have been used but have not achieved the desired clinical outcome.
  • No Access to Clinical Trials: The patient cannot participate in an active clinical trial because of eligibility restrictions, geographical limitations, or lack of available enrollment.

Regulatory Authorities Supporting Expanded Access Programs:

• United States: The FDA Expanded Access Program provides pathways for eligible patients to access investigational medicines outside clinical trials.
• Canada: Health Canada operates the Special Access Program (SAP).
• European Union: The European Medicines Agency (EMA) supports Compassionate Use Programs across member states.
• United Kingdom: The MHRA administers the Early Access to Medicines Scheme (EAMS).
• Australia: The Therapeutic Goods Administration (TGA) supports Special Access Schemes.
• India: The Central Drugs Standard Control Organization (CDSCO) oversees relevant regulatory pathways that may support patient access to unapproved medicines under the Named Patient Program in India.

Types of Patient Access Programs (PAPs):

PAPs may be known by different names globally.

• Expanded Access Program (EAP): Provides access to investigational medicines before commercial approval.
• Compassionate Use Program (CUP): Allows access to investigational therapies for patients with serious or life-threatening conditions.
• Early Access Program: Provides treatment access before a medicine becomes commercially available.
• Managed Access Program (MAP): Supports controlled medicine access under structured frameworks.
• Post-Trial Access Program: Allows patients to continue treatment following participation in a clinical trial.
• Named Patient Program (NPP): Provides access to medicines for individual patients under physician supervision and applicable regulations.

Expanded Access Program vs Named Patient Program vs Compassionate Use:

While terminology differs across countries, the objective is common: to help eligible patients access important therapies before widespread commercial availability.

Therapeutic Areas Commonly Supported Through Expanded Access Programs:

Oncology:

• Lung Cancer
• Breast Cancer
• Melanoma
• Ovarian Cancer
• Gastric Cancer
• Colorectal Cancer
  

Hematology:

• Leukemia
• Lymphoma
• Multiple Myeloma (MM)
• Myelodysplastic Syndromes (MDS)
  

Rare Diseases:

• Genetic Disorders
• Metabolic Diseases
• Ultra-Rare Conditions
  

Neurology:

• Rare Epilepsies
• Neurodegenerative Disorders
• Amyotrophic Lateral Sclerosis (ALS)

Immunology:

• Autoimmune Diseases
• Inflammatory Conditions    

Cell and Gene Therapies:

• Gene-Based Therapies
• Cellular Immunotherapies
• Advanced Precision Medicine Treatments

How Does an Expanded Access Program Work?

Step 1: Medical Evaluation

The treating physician assess the patient's overall condition and determines whether investigational treatment may be appropriate.

Step 2: Eligibility Assessment

The patient is assessed against eligibility requirements.

Step 3: Treatment Identification

An appropriate investigational medicine is identified.

Step 4: Documentation Preparation

Required clinical and regulatory documentation is completed.

Step 5: Regulatory Review

Applicable approvals are obtained where required.

Step 6: Medicine Supply

The investigational medicine is sourced and supplied.

Step 7: Treatment Monitoring

The patient receives ongoing medical supervision and monitoring.

How Physicians and Patients Can Participate in an Expanded Access Program:

Physicians play an important role in determining patient eligibility and managing access requests.

The process generally includes:

• Patient evaluation
• Medical necessity assessment
• Documentation preparation
• Regulatory coordination
• Medicine procurement
• Treatment monitoring
  

Doctors and patients often work with experienced patient access specialists to help navigate these complex procedures compliantly.

Ikris Pharma Network supports patients and physicians in compliant access to investigational medicines across multiple therapeutic areas and geographies.

Key Takeaways:

• Expanded Access Programs (EAPs) provide access to investigational medicines before commercial approval.
• Also known as Compassionate Use Programs, Named Patient Programs, Early Access Programs, and Managed Access Programs.
• Established for patients with serious, life-threatening, or rare diseases.
• Available in many countries under regulatory oversight.
• Commonly used in oncology, hematology, rare diseases, neurology, and immunology.
• Physicians play an important role in determining patient eligibility.
• Ikris Pharma Network supports compliant global patient access solutions.